Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin, Schering Settle Clarinex Patent Dispute; Glenmark, Nycomed Clash Over Cutivate

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Indian drug maker Lupin has settled all its patent litigations with Schering Plough and Sepracor over allergy drug Clarinex (desloratadine). According to the agreement, while the key Clarinex patent expires in 2020, Lupin will gain licenses under the relevant desloratadine patents and will be free to commercially launch its generic desloratadine on July 1, 2012, or earlier in certain circumstances

You may also be interested in...



Pediatric Bioequivalence Studies Are Unnecessary, FDA Says In Rejecting Nycomed Petition

Nycomed had sought additional approval requirements for generic versions of its atopic dermatitis lotion Cutivate.

Pediatric Bioequivalence Studies Are Unnecessary, FDA Says In Rejecting Nycomed Petition

Nycomed had sought additional approval requirements for generic versions of its atopic dermatitis lotion Cutivate.

Ranbaxy and Pfizer Settle Lipitor Litigation

MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel